pharmaphorum

SEPTEMBER 8, 2022

GBS is responsible for nearly half of all life-threatening infections in newborns, and around 15-25% of women carry the bacterium and risk transmitting it to their child in utero, during birth, or during their first months of life. It has previously also been given fast-track status.

Vaccination 52

Vaccination Vaccine Bacterium Licensing 52

pharmaphorum

DECEMBER 24, 2020

AMG 634 – a PDE4 inhibitor being investigated for TB and leprosy complication erythema nodosum leprosum (ENL) – is being licensed to Australia’s Medicines Development for Global Health (MDGH), with Amgen surrendering all rights to the drug. million patients every year and causing over a million deaths.

Bacterium 52

Bacterium Licensing Licensing Development 52

Pharmaceutical Technology

OCTOBER 28, 2022

According to the UK’s National Health Service (NHS), there are over 90 strains of this bacterium. In the same announcement, Pfizer said the company aims to submit a supplemental Biologics License Application (sBLA) to the FDA by the end of the year, depending on discussions with the agency.

Vaccination 162

Vaccination Vaccine Marketing Bacteria 162

XTalks

JULY 25, 2023

Anthrax is a rare, yet severe disease caused by the bacterium B. Additionally, 533 participants received at least one dose of the comparator-licensed anthrax vaccine, BioThrax (Anthrax Vaccine Adsorbed). Kelly Warfield, Emergent’s senior vice president, science and development, in the company’s press release. What Is Anthrax?

FDA Approval 98

FDA Approval Vaccination Vaccine Antibody 98

Roots Analysis

JANUARY 29, 2024

The treatments / products provided by medical aesthetics companies used for facial aesthetic procedures have been mentioned below: Botulinum toxin: It is a toxin produced by a bacterium, Clostridium botulinum , commonly referred to as Botox. These include increased public awareness and the presence of more licensed medical professionals.

Filler 40

Filler Cosmetics Botox Marketing 40

pharmaphorum

MAY 31, 2022

In February, the company reacquired full rights to the shot from Astellas, which paid $10 million upfront to license the vaccine in 2017, clearing the way for GSK’s acquisition. billion in sales last year.

Vaccination 52

Vaccination Vaccine Bacterium Sales 52

XTalks

AUGUST 2, 2023

Late in 2022, AbbVie partnered with HotSpot Therapeutics and announced an exclusive worldwide collaboration and option to license agreement for their interferon regulatory factor 5 (IRF5) inhibitor program for autoimmune disease treatment. In 2022, the FDA proceeded to grant official licensing for Moderna’s Spikevax COVID-19 vaccine.

Sales 98

Sales Manufacturing FDA Approval Life Science 98